At Clementia, we stand with those affected by rare and disabling diseases.
We are inspired by the strength and fortitude of families living with fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), two ultra rare and disabling diseases. We are developing our lead product candidate, palovarotene, for the treatment of FOP, MO and other diseases.
Our team is committed to leveraging our talents and applying our skills and capabilities to drive science forward and develop a pipeline of potential treatment options.
* Phase 1 trials for palovarotene in FOP provide basis for proceeding directly to Phase 2/3 trials in MO
** To our knowledge, no animal models for surgical release in FOP currently exist